This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Perfect Earnings Charts
by Tracey Ryniec
It's not easy to beat every quarter for 5 years, especially during a pandemic. These 5 companies are earnings all-stars.
J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.
Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
by Zacks Equity Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.
Healthcare ETFs Outperform Amid Rising Uncertainties
by Neena Mishra
Investors are seeking refuge in healthcare stocks as inflation and rates rise
Why Johnson & Johnson (JNJ) Might Surprise This Earnings Season
by Zacks Equity Research
Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study
by Zacks Equity Research
The FDA places a partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares fall.
Can Q1 Earnings Bring Strength in Dow ETF?
by Sweta Killa
With some of the blue-chip companies expected to report an earnings surprise, investors should closely monitor the movement of the Dow ETF and grab an opportunity that arises from a surge in any of the 30 stocks.
Is Oshares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA
Johnson & Johnson (JNJ) Stock Moves -1.25%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $179.84, marking a -1.25% move from the previous day.
Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition
by Zacks Equity Research
Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $176.47, moving -0.97% from the previous trading session.
Why the Earnings Surprise Streak Could Continue for Johnson & Johnson (JNJ)
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights UnitedHealth Group, Johnson & Johnson, Alibaba Group Holding, Oracle and Nike
by Zacks Equity Research
UnitedHealth Group, Johnson & Johnson, Alibaba Group Holding, Oracle and Nike have been included in this Analyst Blog.
Top Research Reports for UnitedHealth, Johnson & Johnson, & Alibaba
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ), and Alibaba Group Holding Limited (BABA).
J&J (JNJ) Gets FDA Nod for HIV Jab, Cabenuva, in Adolescents
by Zacks Equity Research
The FDA approves Johnson & Johnson's (JNJ) Cabenuva for treating HIV-1 in virologically suppressed adolescents aged 12 years and above.
Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QUS
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $177.83, moving +0.51% from the previous trading session.
Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIG
Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma
by Zacks Equity Research
Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.
Pfizer's (PFE) Etrasimod Meets Ulcerative Colitis Study Goals
by Zacks Equity Research
Pfizer's (PFE) late-stage candidate etrasimod achieves statistical significance in its primary endpoint of clinical remission in an ulcerative colitis study.
Ligand (LGND) Inks Merger Deal With SPAC for OmniAb Spin-Off
by Zacks Equity Research
Ligand (LGND) is on track to spin-off its OmniAb business in the second half of 2022. It signs a merger agreement with a special purpose acquisition company (SPAC), Avista Public Acquisition Corp. for the same.
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pfizer (PFE) Recalls Hypertension Drug Due to Impurities
by Zacks Equity Research
Pfizer (PFE) is recalling six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.
Should Vanguard Value ETF (VTV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTV
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $175.83 in the latest trading session, marking a +0.57% move from the prior day.